SEALSQ Noses Higher on Enhanced Platform Word
SEALSQ Corp (NASDAQ: LAES) shares just cleared breakeven. Thursday. The Geneva, Switzerland-based company, which focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a significant enhancement to its trusted INeS PKI platform, which now includes secure code signing services designed to protect the integrity of firmware distributed across connected devices. This new capability positions INeS as a future-proof trust infrastructure for manufacturers needing to secure over-the-air (OTA) firmware updates in compliance with emerging global cybersecurity regulations.INeS now supports firmware signing with both legacy ECC (Elliptic Curve Cryptography, RSA algorithms, enabling customers to meet today’s performance and regulatory needs while preparing for the quantum era.“With global regulations such as the EU Cyber Resilience Act, NIS2, and U.S. Executive Order 14028 raising the bar on software supply chain security, firmware integrity has become mission-critical,” said Gweltas Radenac, IoT Security Business Line Director of SEALSQ. “By integrating code signing into our INeS platform, SEALSQ delivers a scalable, standards-based, and post-quantum-ready trust infrastructure for OEMs across IoT, Medical Device, and critical infrastructure such as Smart Grid.”LAES shares gained 2.5 cents to $2.76.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


